For the Inventor, By the Inventor

Enter assignee name

Impact Therapeutics, Inc.

USPTO Granted Patents = 11

EPO Patents = 9

Forward Citations = 25

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Ye Edward Tian (8 out of 16 patents)

Sui Xiong Cai (5 out of 11 patents)

Suixiong Cai (5 out of 9 patents)

4. Qingbing Xu (4 out of 4 patents)

5. Lizhen Wu (4 out of 5 patents)

6. Lijun Liu (4 out of 5 patents)

7. Yangzhen Jiang (4 out of 4 patents)

8. Guoxiang Wang (4 out of 4 patents)

9. Feng Yin (4 out of 5 patents)

10. Chengyun Gu (4 out of 4 patents)

11. Xiuhua Hu (4 out of 4 patents)

12. Xiaozhu Wang (4 out of 10 patents)

13. Sishun Kang (4 out of 4 patents)

14. Shengzhi Chen (4 out of 4 patents)

15. Haijun Dong (3 out of 5 patents)

11 patents: Sort by Forward Citations

1. 11358955 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2022-06-14),

2. 11179392 - Solid pharmaceutical formulation of PARP inhibitors and use thereof (2021-11-23),

3. 10874670 - Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof (2020-12-29),

4. 10703759 - 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones (2020-07-07),

5. 10676468 - N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof (2020-06-09),

6. 10562889 - Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones (2020-02-18),

7. 10316027 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2019-06-11),

8. 9926304 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2018-03-27),

9. 9290460 - [object Object] (2016-03-22),

10. 9102631 - 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof (2015-08-11),

11. 9090568 - Quinazolinediones and their use (2015-07-28),

Impact Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for the treatment of cancer. We aim to provide novel solutions that will have a positive impact on patients' lives. Our team of experienced scientists and researchers is dedicated to discovering and developing breakthrough drugs that target specific cancer-related molecular pathways. Through our cutting-edge research and collaborations, we strive to bring transformative treatments to cancer patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

11 Patents

#40 in Nanjing

#2,539 in China

#51,671 in the World

Impact Therapeutics, Inc.

Forward Citations = 25

27 inventors:

Ye Edward Tian (8 out of 16 patents)

Sui Xiong Cai (5 out of 11 patents)

Suixiong Cai (5 out of 9 patents)

4. Qingbing Xu (4 out of 4 patents)

5. Lizhen Wu (4 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…